Repeated measurements of HCV-RNA levels may help to optimize IFN free treatment. HCV-RNA on treatment TND: target not detected LLOQ: lower limit of quantification Disclosures: Andreas Maieron – Advisory Committees or Review Panels: MSD, Jannsen, BMS,
BVdhringer Ingelheim, Gilead; Grant/Research Support: Roche; Speaking and Teaching: Roche, MSD, Jannsen, Gilead Rudolf E. Stauber – Advisory Committees or Review Panels: Gilead, Janssen-Cilag, AbbVie, BMS; Grant/Research Support: JNK inhibitor MSD; Speaking and Teaching: Roche Hermann Laferl – Advisory Committees or Review Panels: BMS; Grant/Research Support: Roche Austria, Janssen Cilag, Gilead Markus Peck-Radosavljevic – Advisory Committees or Review Panels: Bayer, Gil-ead, Janssen, BMS, AbbVie; Consulting: Bayer, Boehringer-Ingelheim, Jennerex, Eli Lilly, AbbVie; Grant/Research Support: Bayer, Roche, Gilead, MSD; Speaking and Teaching: Bayer, Roche, Gilead, MSD, Eli Lilly Peter Ferenci – Advisory Committees or Review Panels: Roche, Idenix, MSD, Jans-sen, AbbVie, BMS, Tibotec, BVdhringer Ingelheim; Patent Held/Filed: Madaus Rottapharm; Speaking and Teaching: Roche, Gilead, Roche, Gilead, Salix Harald Hofer – Speaking and Teaching: Janssen, Roche, MSD, Gilead, Abbvie The following people have nothing
to disclose: Karin Kozbial, selleckchem Robert Paul Strassl, Ramona Al Zoairy, Michael P. Strasser, Thomas Bamberger, Albert Staetter-mayer, Heinz M. Zoller, Peter Knoflach, Katharina Staufer, Petra E. Steindl-Munda, Wolfgang Vogel Background & Aim: High sustained virologic response (SVR) rate has been reported in triple therapy with simeprevir (SMV), pegylated interferon (Peg-IFN) and ribavirin (RBV) for patients with chronic hepatitis C (CH-C) genotype 1. A strong association between rapid virologic response (RVR) and SVR has been reported in phase 3 trial from Japan. The factors
associated with rapid virologic response (RVR) were examined in this study. Patients check details & Methods: This study was conducted at Osaka University Hospital and institutions participating in the Osaka Liver Forum. A total of 245 patients with CH-C (117 males, 128 females; mean age 62.1 y.o., 107 Naïve patients, 101 Peg-IFN/RBV experienced patients) were treated with SMV, Peg-IFN alfa-2a (180 μg/week) or alfa-2b (1.5 μg/kg/week) and RBV (600-1000 mg/day). The serum HCV RNA level was assessed qualitatively by the COBAS TaqMan HCV test, v2.0 (<15 IU/ml). Results: Of the 245 patients, 4 patients discontinued therapy in the initial 4 weeks (1.6%; fun-dal hemorrhage, n = 1 and eruption, n = 3). The RVR rates were 77% in all patients; 85% in Naive, 88% in relapser and 55% in non-responder (NR). There were no patients with viro-logic breakthrough. In univariate analysis, previous IFN history and response (p < 0.001), HCV RNA level (p = 0.003), liver fibrosis stage (p = 0.019), platelet counts (p = 0.002), yGTP level (p = 0.026), AFP level (p = 0.001), IL28B SNP (p = 0.